At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
Displaying 351–360 of 615 results.
-
The usual approach to managing HPV-related oropharynx cancer in people whose tumors have a higher risk of coming back after surgery is to use radiation therapy to prevent tumor relapse. However, not all patients have tumors that come back after surgery, and many may not need radiation therapy at all, or only need it later when there are early signs of the cancer coming back.
-
Researchers want to see if adding autogene cevumeran to nivolumab is better than nivolumab alone to treat urothelial (bladder) cancer. The people in this study have muscle-invasive urothelial cancer (MIUC) that has been removed with surgery.
-
Researchers want to learn if BGB-11417 given alone or with dexamethasone and carfilzomib may help people with multiple myeloma. The people in this study have multiple myeloma that keeps growing after standard treatment. BGB-11417 blocks a protein called Bcl-2 that helps multiple myeloma cells to live and grow.
-
Researchers are comparing several combination drug treatments for people with cancer of the stomach or gastroesophageal junction (GEJ). The people in this study have gastric or GEJ cancer that metastasized (spread) or is inoperable (cannot be surgically removed). In addition, their tumors make a protein called HER2.
-
Urothelial cancers can grow in different parts of the urinary tract. This includes the ureter (the tube that carries urine from the kidneys to the bladder) and renal pelvis. The renal pelvis is where the ureter connects to the kidneys. The standard treatment is surgery to remove the ureter, kidney, or both. In this study, researchers want to see if enfortumab vedotin, given before surgery, is useful for treating urothelial cancers. The people in this study have high-risk urothelial cancers of the upper urinary tract. High risk means there is a greater chance of the cancer coming back after treatment.
-
Autologous stem cell transplant (ASCT) is a standard treatment for multiple myeloma. An ASCT replaces the blood-forming cells destroyed by disease or treatment with healthy cells collected from your blood. Before ASCT, people generally receive a standard drug, melphalan, to prepare the body for the transplant.
-
Trastuzumab is an anticancer medication that targets HER2, a protein overproduced by some cancers of the stomach (gastric cancers) and the junction between the stomach and esophagus (gastro-esophageal junction or GEJ cancers). In this study, researchers are evaluating the safety of combining the drug trastuzumab deruxtecan (T-DXd) with immunotherapy and/or chemotherapy in patients with inoperable or metastatic stomach and GEJ cancers that have come back or continued to grow despite prior treatment.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
Researchers want to know if eating a plant-based diet and taking certain nutritional supplements may be helpful for reducing the risk of progression to multiple myeloma in people with monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM). People with MGUS and SMM have an abnormal protein called the M protein in their blood and are at risk of developing multiple myeloma.